NCT06955832

Brief Summary

The goal of this observational study is to compare the diagnostic accuracy of Phase-Sensitive Inversion Recovery (PSIR) MRI versus conventional T2-weighted (T2W) and Fluid Attenuated Inversion Recovery (FLAIR) sequences in detecting early brain lesions in patients with Multiple Sclerosis (MS). The study will include male and female participants aged 15-65 years diagnosed with MS per the 2017 McDonald criteria. This study hypothesizes that:

  • PSIR MRI will detect a significantly higher number of cortical lesions (intracortical, leukocortical, and juxtacortical) compared to conventional T2W and FLAIR sequences in MS patients (p \< 0.05).
  • Lesions identified exclusively by PSIR will correlate more strongly with clinical measures (EDSS disability scores and SDMT cognitive performance) than those detected by T2W/FLAIR alone, suggesting PSIR's superior sensitivity to clinically relevant pathology.

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
30

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jun 2025

Shorter than P25 for all trials

Geographic Reach
1 country

3 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

April 25, 2025

Completed
7 days until next milestone

First Posted

Study publicly available on registry

May 2, 2025

Completed
1 month until next milestone

Study Start

First participant enrolled

June 1, 2025

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2025

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2025

Completed
Last Updated

May 18, 2025

Status Verified

May 1, 2025

Enrollment Period

Same day

First QC Date

April 25, 2025

Last Update Submit

May 14, 2025

Conditions

Keywords

Multiple SclerosisCortical lesionsMRIEarly diagnosisMcDonald criteria

Outcome Measures

Primary Outcomes (1)

  • Number and classification of cortical lesions

    Total cortical lesion count (sum of intracortical \[IC\], leukocortical \[LC\], and juxtacortical \[JC\] lesions) detected by each MRI sequence (PSIR vs. T2W vs. FLAIR), assessed by two independent neuroradiologists.. Lesion subtype distribution: * IC lesions (confined to gray matter). * LC lesions (spanning gray-white matter). * JC lesions (subcortical U-fiber involvement).

    18 months

Eligibility Criteria

Age15 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

This study will enroll participants from three clinical sites in Egypt: * Neurology Department, Banha University Hospitals (Benha, Qalyubia Governorate). * El Mounira MS Unit (Cairo). * Naser Specialized Hospital MS Unit (Cairo). Recruitment Setting: * Outpatient MS clinics at all three sites * Inpatient neurology services at Banha University Hospitals

You may qualify if:

  • Age between 15-65 years.
  • Both sexes.
  • Patients with MS according to McDonald Criterion

You may not qualify if:

  • Age less than 15 years old.
  • Patients with stroke or previous intracranial hemorrhage.
  • Contraindications to MRI scans.
  • MS mimics.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Banha University Hospitals

Banhā, Qalyubia Governorate, Egypt

RECRUITING

El Mounira Multiple Sclerosis Unit

Cairo, Egypt

RECRUITING

Naser Institute MS Unit

Cairo, Egypt

RECRUITING

MeSH Terms

Conditions

Multiple SclerosisDisease

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNSAutoimmune Diseases of the Nervous SystemNervous System DiseasesDemyelinating DiseasesAutoimmune DiseasesImmune System DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Neurology Specialist

Study Record Dates

First Submitted

April 25, 2025

First Posted

May 2, 2025

Study Start

June 1, 2025

Primary Completion

June 1, 2025

Study Completion

October 1, 2025

Last Updated

May 18, 2025

Record last verified: 2025-05

Locations